Active Ingredient: Tirzepatide
Tirzepatide is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise:
For this indication, competent medicine agencies globally authorize below treatments:
For:
Regimen A: Subcutaneous, 2.5 milligrams tirzepatide, once weekly, over the duration of 4 weeks. Afterwards, subcutaneous, 5 milligrams tirzepatide, once weekly.
Regimen B: Subcutaneous, 2.5 milligrams tirzepatide, once weekly, over the duration of 4 weeks. Afterwards, subcutaneous, 5 milligrams tirzepatide, once weekly, over the duration of 4 weeks. Afterwards, subcutaneous, 7.5 milligrams tirzepatide, once weekly, over the duration of 4 weeks. Afterwards, subcutaneous, 10 milligrams tirzepatide, once weekly.
Regimen C: Subcutaneous, 2.5 milligrams tirzepatide, once weekly, over the duration of 4 weeks. Afterwards, subcutaneous, 5 milligrams tirzepatide, once weekly, over the duration of 4 weeks. Afterwards, subcutaneous, 7.5 milligrams tirzepatide, once weekly, over the duration of 4 weeks. Afterwards, subcutaneous, 10 milligrams tirzepatide, once weekly, over the duration of 4 weeks. Afterwards, subcutaneous, 12.5 milligrams tirzepatide, once weekly, over the duration of 4 weeks. Afterwards, subcutaneous, 15 milligrams tirzepatide, once weekly.
The starting dose of tirzepatide is 2.5 mg once weekly. After 4 weeks, the dose should be increased to 5 mg once weekly. If needed, dose increases can be made in 2.5 mg increments after a minimum of 4 weeks on the current dose.
The recommended maintenance doses are 5, 10 and 15 mg.
The maximum dose is 15 mg once weekly. When tirzepatide is added to existing metformin and/or sodium-glucose co-transporter 2 inhibitor (SGLT2i) therapy, the current dose of metformin and/or SGLT2i can be continued.
When tirzepatide is added to existing therapy of a sulphonylurea and/or insulin, a reduction in the dose of sulphonylurea or insulin may be considered to reduce the risk of hypoglycaemia. Blood glucose self-monitoring is necessary to adjust the dose of sulphonylurea and insulin. A stepwise approach to insulin reduction is recommended.
If a dose is missed, it should be administered as soon as possible within 4 days after the missed dose. If more than 4 days have passed, skip the missed dose and administer the next dose on the regularly scheduled day. In each case, patients can then resume their regular once weekly dosing schedule.
The day of weekly administration can be changed, if necessary, as long as the time between two doses is at least 3 days.
No dose adjustment is needed based on age. Only very limited data are available from patients aged ≥85 years.
To be injected subcutaneously in the abdomen, thigh or upper arm.
The dose can be administered at any time of day, with or without meals.
Injection sites should be rotated with each dose. If a patient also injects insulin, they should inject tirzepatide into a different injection site.
Liability Disclaimer : RxReasoner has utilized reasonable care in providing content and services that are accurate, complete and up to date. However, RxReasoner does not accept any responsibility or liability about it. The content and services of RxReasoner are for informational purposes only and they are not intended to be a substitute for the knowledge, expertise, skill, and judgment of physicians, pharmacists, nurses, or other healthcare professionals involved in patient care. RxReasoner offers no medical advice. Users are responsible for the use of the provided content. A shown indication or treatment should not be construed to indicate that the medication is safe, appropriate, or effective in any given patient or under any particular circumstances. The absence of an indication or treatment should not roule out the existence of other appropriate medications. Always seek the advice of a physician or other qualified health provider with any questions you may have regarding a medical condition or medicament. RxReasoner is not liable for any damages allegedly sustained arising out of the use of its content and services.
